Other Information
−Removed: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended June 30, 2025, as such terms are defined under Item 408 (a) of Regulation S-K.
−Removed: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended June 30, 2025.
−Removed: Asset Purchase and Contribution Agreement, dated as of May 9, 2025, by and among Hope Therapeutics, Inc.
−Removed: and the signatories thereto (incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2025.
−Removed: Membership Interest Purchase and Contribution Agreement, by and among Hope Therapeutics, Inc.
−Removed: and the signatories thereto (incorporated by reference to Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2025.
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended September 30, 2025, as such terms are defined under Item 408 (a) of Regulation S-K.
+Added: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended September 30, 2025.
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
NRX PHARMACEUTICALS, INC.
−Removed: August 15, 2025
+Added: November 14, 2025
/s/ Jonathan Javitt
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.